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oo.com (W. SuttithawiSummary We report a case of successful, long-term pleurovenous shunt (PVS) in
treating refractory nonmalignant hepatic hydrothorax. An 82-year-old woman with
liver cirrhosis, hypertension complicated with chronic renal failure while on
hemodialysis, presented with progressive dyspnea in association with a recurrent
right-sided pleural effusion, occurring secondary to transdiaphragmatic migration of
ascites. The diagnosis was established by a demonstration of 99mTc-sulphur colloid
sequential scintigraphic scan. Despite repetitive thoracenteses and traditional
medical treatment, she suffered dyspnea without relief. Denver peritoneovenous
shunt was inserted into the right-sided pleural cavity to drain effusion into the
subclavian vein without short- and long-term complications. Manually pumping
schedule of 10min was performed twice daily to remove pleural fluid into the venous
circulation for maintaining shunt patency. After 19 months of follow-up, the patient
is doing well and PVS remains patent without significant pleural effusion. PVS opens
a window of opportunity and offers an alternative procedure with minimal
invasiveness for high-risk patients with refractory hepatic hydrothorax. It could be
an alternative treatment to other conventional surgical interventions.
& 2005 Elsevier Ltd. All rights reserved.Introduction
Hepatic hydrothorax, an uncommon manifestation
of end-stage liver disease complicated with portalElsevier Ltd. All rights reserv
nd Critical Care Medicine,
Soi 3, Bangkok 10110,
6 2 667 2525.
c.th,
l).hypertension, occurs approximately in 5% of all
cirrhotic patients. At least five mechanisms are
postulated to be the causes: direct access through
diaphragmatic defects, passage of fluid via dia-
phragmatic lymphatics, thoracic duct lymphatic
leakage, azygous vein hypertension and hypoalbu-
minemia. It affects one or both sides with 85%
involvement predominantly on the right, 13% on the
left, and 2% on bilateral pleural cavities.1 Gener-
ally, it occurs with a small-to-moderate volume ofed.
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ascites as well.2
The goal of management is to relieve dyspnea
and improve the patient’s quality of life. Tradi-
tional medical treatment such as a restriction of
dietary sodium and diuretic administration is the
initial form of therapy. In case of unresponsiveness
to the aforementioned treatment, surgical inter-
ventions have been performed subsequently. The
simplest method is serial thoracenteses. Tube
thoracostomy is contraindicated since it can cause
a large volume of fluid, nutritional loss and inability
to remove the chest tube. Other methods of
treatment included thoracoscopy to repair dia-
phragmatic defects with talc pleurodesis, reduction
of portal hypertension by side-to-side porto-caval
shunt and transjugular intrahepatic portosystemic
shunt (TIPS), removal of ascites by peritoneovenous
shunt and liver transplantation.1 However, these
interventions carry some risks and undesirable side
effects. We report a case of successful, long-term
pleurovenous shunt (PVS) as an alternative proce-
dure to conventional interventions.Case report
An 82-year-old female with hypertension compli-
cated with renal failure had undergone hemodia-
lysis three times weekly in the past 3 years. Two
years ago, she developed progressive dyspnea,
ascites and pedal edema together with an enlarge-
ment of the liver and the spleen. Chest and
abdominal examination revealed decreased breathFigure 1 (A) Chest radiograph demonstrated opacity of mor
showed massive right-sided pleural effusion without mass,
ascites with enlargement of the liver and spleen, (D) 99mTc-s
appearance of radiolabeled tracer, migrating from the perito
radiograph, 1-month after shunting placement, revealed nearsounds over the right lung, slightly distended
abdomen with hepatosplenomegaly and moderate
amount of ascites. She denied alcoholic consump-
tion, hepatitis and blood transfusion. Laboratory
studies showed hemoglobin of 11 g/dL and a serum
albumin of 2.9 g/dL. Serological study for hepatitis
B and C was negative. Chest radiographs showed
opacity of more than half of right hemithorax
(Fig. 1A). The computed tomography (CT) of the
chest demonstrated massive right-sided pleural
effusion without mass (Fig. 1B). CT of the abdomen
demonstrated liver cirrhosis without portal vein
thrombosis (Fig. 1C). Echocardiography revealed
normal ejection fraction. Thoracentesis and ab-
dominal paracentesis revealed approximately the
same clear, transudative pleural and peritoneal
fluid which contained a WBC count of 0.13 109/L
(97% lymphocytes), a protein of 34 g/L (a serum
level of 67 g/L) with a serum-to-pleural and
peritoneal albumin gradient of 1.8 g/dL, LDH and
ADA of 150 IU/L and 14mg/mL, respectively.
Microbiological and cytological studies yielded
negative results.
Repetitive thoracentesis was performed biweekly
with increasing frequency to twice a week to
ameliorate dyspnea. Sequential scintigraphic scan
was performed to establish hepatic hydrothorax by
intraperitoneal injection of the 99mTc-sulphur col-
loid and the radiolabeled tracer appeared in the
right-sided pleural cavity in just minutes subse-
quently (Fig. 1D). Denver peritoneovenous shunt
(Denver Biomedical, Colorado, USA) was implanted
into the right-sided pleural space instead of the
peritoneal cavity with the venous end and tunneled
subcutaneously and inserted into the subclaviane than half of the right hemithorax, (B) CT of the chest
(C) CT of the abdomen demonstrated liver cirrhosis and
ulphur colloid sequential scintigraphic scan revealed the
neal cavity into the entire right hemithorax and (E) chest
ly complete resolution of the right-sided pleural effusion.
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chamber was located over the ribs, under the
subcutaneous tissue and pumped manually for
10min twice daily while lying supine. By the end
of the first month after shunting, her condition was
greatly improved with nearly complete resolution
of the pleural effusion (Fig. 1E) with an increasing
albumin from 2.9 to 3.7 g/dL. At the end of the
fourth month, she had a markedly improved quality
of life and could resume ordinary activities with
partial assistance.Discussion
Currently, TIPS is the procedure of choice for
hepatic hydrothorax in case of unresponsiveness
to conventional medical treatment.1,4 It has a
successful rate between 58% and 91%, depending
on the criteria used to assess success and has some
disadvantages such as shunt occlusion associated
with recurrent hydrothorax in 50%,5 procedure-
related sepsis in 4.2% and hepatic encephalopathy
in 37.5%.6
The aim of peritoneovenous shunting is to divert
ascites into the venous circulation.7 However, in
hepatic hydrothorax, more negative pressure in the
pleural cavities makes this shunt ineffective.8 Some
authorities applied it alternatively as a PVS to drain
pleural fluid effectively.9,10
By following the algorithm on the management of
hepatic hydrothorax, liver transplantation will be
considered whenever the patients are not respond-
ing to TIPS.1,4 However, some patients may not
undergo this procedure due to co-morbidities of
high risk for interventions.
Even though LeVeen et al.7 initially introduced
peritoneovenous shunt for draining ascites in 1974,
Pollock first demonstrated PVS in 1975. The author
implanted a peritoneo-atrial Holter valve to drain
malignant pleural effusion into the superior vena
cava.9 Oizumi et al.10 reported the effectiveness of
this shunt with the duration of 2 months. Much
longer-term, successful application with extensions
into the other indications such as nephrotic
syndrome was described by Artemiou et al.3 in
2003. There were six cases of hepatic hydrothorax
in this series. One death occurred within 4 weeks
due to hepatic failure, irrelevant to the procedure.All shunts patency was with an average duration of
13.3 months without other treatment for pleural
effusion. However, long-term patency and compli-
cations of this shunt remains currently unknown.
This report confirms that this device can work well
by the manually pumping schedule of 10min twice
daily and is free of complications for as long as 19
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